Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571192 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
A Phase 1 study, sponsored by Mirum Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02571192: Completed Phase 1 study, sponsored by Mirum Pharmaceuticals.
NCT02571192 is a Phase 1 study that has completed, run by Mirum Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02571192, a Phase 1 study, has completed, sponsored by Mirum Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
Interventions
- DRUG SHP626
- RADIATION 5.95 μCi RAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-10-01 |
| Est. Completion | 2015-10-01 |
| Phase | Phase 1 |
What the finished NCT02571192 record still lists
NCT02571192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which SHP626 is the first listed.
NCT02571192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02571192 about?
NCT02571192 is a clinical study titled "A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose". The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.
What is the current status of trial NCT02571192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-10-01. Estimated completion is 2015-10-01.
What interventions are being tested in trial NCT02571192?
The interventions under investigation include: SHP626 (DRUG), 5.95 μCi RAD (RADIATION).
Who is sponsoring clinical trial NCT02571192?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02571192's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI